Collectively, our findings confirmed the association of SETD2 deletion with prognostic outcome and therapeutic response in cutaneous melanoma patients, providing novel insights into the functional role of SETD2 in melanoma and a potential mechanism whereby SETD2 influences the prognosis of melanoma patients as well as treatments. Here, SETD2 is linked to melanoma.